Brukinsa

Chemical Namezanubrutinib
Dosage FormCapsule (oral; 80 mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyBeiGene
Approval Year2019

Indication

  • Brukinsa is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Last updated on 10/20/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Brukinsa (zanubrutinib) Prescribing Information2019BeiGene